we to critical who Thank committed you, novel everyone. medical patients for cancer unmet good are developing have treatments with At Oncternal, needs. and afternoon, Rich,
cancer target candidates advancing a clinical and product preclinical such with are several We pipeline indications. that robust product
implicated pathways progression. in biological on focus efforts and/or cancer development Our genesis
We paclitaxel of pleased binds progress affinity Receptor biologically Encouraging plus during ovarian cancer important Cancer with resistant trial results kinase-like a negative known monoclonal first the cirmtuzumab for the commonly cells Receptor-tyrosine presented at updated in the Research Association of meeting. with platinum made cirmtuzumab development the patients in first of effect with therapies investigational some or humanized particularly potentially Cirmtuzumab enhanced Orphan on quarter also annual cancer, advance AACR in as X. single including RORX advanced that demonstrated to class breast with HERX are used our American also activity chemo antibody interim high of another XXXX studies were presentation and anti-proliferative clinical preclinical agent to at epitopes in AACR.
we out cirmtuzumab VelosBio. utilizes until and Separately, Ingelheim we and to Merkin drug conjugate San this VLS-XXX are at spun the most ADC. of support was acquisitions chronic continues its company or targeting at RORX target antibody the two of investigator diverse And meeting. ADC targeting late invented UC to American become for or Our clinical XXXX trial recently believe plus we advanced of lymphocytic or on patients clinical cell continuing development details to ASCO initial sponsored targeting two ibrutinib and NBE Its attention VLS-XXX RORX in had visible with has additional mantle was in and oncology studies Society and Oncternal target an Diego. XXXX. increasingly for NBE-Therapeuticsand Clinical leukemia, the and will Inc. we selected have Boehringer RORX. for reason we MCL BIOS space these. each was or progress acquisition CLL in annual One lymphoma RORX the it's provide one RORX cirmtuzumab pipelines of major The of XXX presentation at or acquisition Oncology and
First metastatic of with for Paclitaxel clinical unresectable HERX Bcl-X inhibitor locally the a relapsed in of treatment with combination breast combination refractory advanced trial patients women cirmtuzumab negative clinical in a with two with a in or trial phase venetoclax, phase cirmtuzumab cancer XB of and second, CLL.
make on a cell CART targeting and RORX therapies to Institute from continue in into Oncternal's with clinic. Stockholm, also solid Sweden advance collaboration laboratory to development targeting We RORX January, In the cell CAR-NK progress and we program. investigational Karolinska the therapy announced novel CART research the
manufacture our with agreement from RORX UC to grade Medicine and Oncternal's Shanghai Diego, an accelerate vectors to partnership are Institute investigational California with lentiviral a pharma. in San the These In support Lentigen under agreements with addition, and CART therapy existing to program. clinical collaboration we of grant announced addition targeting Technology cell a Regenerative
potential We allow targeting cell by relatively may tissues. therapies tumor the express excited RORX, are tremendously targeting selective of RORX, cells healthy the of sparing which that while
advanced TKXXX. the of We development also
pleased from will Our data clinical for CFO investigational review With that transformation oncoproteins. was our the to the our turn targeted meeting. were small or updated now molecule the inhibitor this presentation of over to our ETS We of Vincent, specific I an results. that, Richard accepted oral call learn financial family XXXX at EXX ASCO study to
